Android app Apple app link

Australia's CSL delays spin-off as US flu vaccine rates decline

By Yahoo! Finance   |   1 month ago
Australia's CSL delays spin-off as US flu vaccine rates decline

Australian biotech CSL delayed its vaccine division spin-off and reduced earnings forecasts due to declining U.S. flu vaccination rates, causing shares to drop 16.6%. The company aims to spin off CSL Seqirus when market conditions are favorable for shareholder value.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.